Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Chair: Rx&D Collaborative Research Program

University of Toronto

$210,000.00

Biomarkers of Disease Activity and Progression in IgA Nephropathy

FY 2010-11

Summary
Over six thousand Canadians develop end stage renal disease (ESRD) each year requiring either dialysis treatment or kidney transplantation. Diseases of the filter of the kidney (the glomerulus) account for the majority of cases of ESRD. The current proposal will focus on one of the most common diseases of the kidney filter: IgA Nephropathy (IgAN). The clinical course of IgAN is notoriously variable although almost 40% of patients will eventually develop ESRD. The goal of the proposed research program is to identify proteins in the urine that will enable doctors to more accurately predict the clinical course of IgAN and in particular to identify both "high risk" and "low risk" patients. The experimental approach is based on the measurement of gene expression in kidney tissue from patients with IgAN that we have already performed, and the proteins from two gene sets will be targeted for measurement in the urine of subjects with IgAN. The gene sets are linked to measures of kidney function. In order to perform these studies we will utilize a biobank of kidney tissue samples and urine samples linked to a database of long-term clinical data. Ultimately the identification of a set of proteins in the urine related to good clinical outcomes and bad clinical outcomes in our database should enable us to identify "high risk" and "low risk" at the time of diagnosis. The identification of "high risk" individuals will influence treatment decisions and facilitate early interventions designed to prevent progression to ESRD. Similarly, the identification of "low risk" individuals - those likely to have a benign course regardless of intervention - will also influence treatment decisions and spare patients from the toxicity of unnecessary therapy.
Program
Chair: Rx&D Collaborative Research Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
206722
Name
Scholey James W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Gender and Health
Theme2
Biomedical
Prcname2
CIHR/Rx&D Research Chairs
Projecttitle
Biomarkers of Disease Activity and Progression in IgA Nephropathy
Programtype2
Salary Programs
Orgnameinp2
University of Toronto
Cihramount2
$210,000
Cihrequipment2
$0
Programname2
Chair: Rx&D Collaborative Research Program
Keyworddelim
Cell Signaling : Rhoa/Akt/Erk/Egf Receptor; Chronic Kidney Disease; Mesangial Cell; Proteinuria; Proximal Tubule Cell
Abstract
Over six thousand Canadians develop end stage renal disease (ESRD) each year requiring either dialysis treatment or kidney transplantation. Diseases of the filter of the kidney (the glomerulus) account for the majority of cases of ESRD. The current proposal will focus on one of the most common diseases of the kidney filter: IgA Nephropathy (IgAN). The clinical course of IgAN is notoriously variable although almost 40% of patients will eventually develop ESRD. The goal of the proposed research program is to identify proteins in the urine that will enable doctors to more accurately predict the clinical course of IgAN and in particular to identify both "high risk" and "low risk" patients. The experimental approach is based on the measurement of gene expression in kidney tissue from patients with IgAN that we have already performed, and the proteins from two gene sets will be targeted for measurement in the urine of subjects with IgAN. The gene sets are linked to measures of kidney function. In order to perform these studies we will utilize a biobank of kidney tissue samples and urine samples linked to a database of long-term clinical data. Ultimately the identification of a set of proteins in the urine related to good clinical outcomes and bad clinical outcomes in our database should enable us to identify "high risk" and "low risk" at the time of diagnosis. The identification of "high risk" individuals will influence treatment decisions and facilitate early interventions designed to prevent progression to ESRD. Similarly, the identification of "low risk" individuals - those likely to have a benign course regardless of intervention - will also influence treatment decisions and spare patients from the toxicity of unnecessary therapy.
Competitiondate
201005
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Scholey, James W
Approvedterm
3 ans 0 mois
Cihrcontribution2
Patient Oriented Research~ $210,000~ $0~